# HLX26

Source: https://onco.cc/drugs/hlx26/  
OnCo record `hlx26` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

HLX26 is an experimental monoclonal antibody from Shanghai Henlius Biotech in phase 2 trials for non-small-cell lung cancer, aimed at LAG-3.

## Summary

HLX26 is a monoclonal antibody developed by Shanghai Henlius Biotech. Its target is LAG-3 (the sponsor names LAG-3). The sponsor states: An anti-LAG-3 monoclonal antibody injection that blocks LAG-3 signalling to enhance T-cell mediated anti-tumour immunity, studied in combination with PD-1 inhibition and chemotherapy. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in non-small-cell lung cancer. The largest, NCT05787613, plans to enrol 132 participants with primary completion was scheduled for 2026-02 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Also known as: Anti-LAG-3 monoclonal Antibody Injection
- Tags: pipeline; ctgov-ingest
- Modality: monoclonal antibody
- Mechanism: An anti-LAG-3 monoclonal antibody injection that blocks LAG-3 signalling to enhance T-cell mediated anti-tumour immunity, studied in combination with PD-1 inhibition and chemotherapy.

## Sources

- ClinicalTrials.gov: trials of HLX26: https://clinicaltrials.gov/search?intr=HLX26

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- targets: [LAG-3](https://onco.cc/targets/lag3/)
- companies: [Shanghai Henlius Biotech](https://onco.cc/companies/henlius/)
- trials: [A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients](https://onco.cc/trials/nct05787613/)

---
JSON: https://onco.cc/api/v1/entities/hlx26.json